34.52
-0.60 (-1.71%)
| Penutupan Terdahulu | 35.12 |
| Buka | 34.92 |
| Jumlah Dagangan | 17,377,881 |
| Purata Dagangan (3B) | 34,589,974 |
| Modal Pasaran | 142,502,494,208 |
| Harga / Pendapatan (P/E TTM) | 31.10 |
| Harga / Pendapatan (P/E Ke hadapan) | 21.64 |
| Harga / Jualan (P/S) | 6.45 |
| Harga / Buku (P/B) | 2.84 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Mar 2026 |
| Margin Keuntungan | 17.97% |
| Margin Operasi (TTM) | 27.38% |
| EPS Cair (TTM) | 0.850 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 18.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 63.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.86% |
| Nisbah Semasa (MRQ) | 2.73 |
| Aliran Tunai Operasi (OCF TTM) | 5.22 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.30 B |
| Pulangan Atas Aset (ROA TTM) | 5.05% |
| Pulangan Atas Ekuiti (ROE TTM) | 8.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | WUXI BIO | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -0.5 |
| Purata | -1.00 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| WUXI BIO | 143 B | - | 31.10 | 2.84 |
| INNOVENT BIO | 146 B | - | 111.97 | 8.89 |
| SINO BIOPHARM | 117 B | 1.15% | 27.21 | 2.85 |
| AKESO | 104 B | - | - | 13.98 |
| PHARMARON | 54 B | 0.92% | 20.42 | 2.23 |
| BEONE MEDICINES | 296 B | - | 663.87 | 7.45 |
|
WuXi Biologics is one of the largest global biologic global contract development and manufacturing organizations. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 18.7 billion. North America represented 57.3% of total revenue in 2024. The firm has a "follow and win the molecule" strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Core |
| % Dimiliki oleh Orang Dalam | 13.07% |
| % Dimiliki oleh Institusi | 35.91% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |